Cocrystal Pharma, Inc. (COCP)

Cocrystal Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	-	-	-	2.01
Revenue Growth (YoY)	-	-	-	-	-69.32%
Cost of Revenue	-	15.17	12.39	8.79	6.03
Gross Profit	-	-15.17	-12.39	-8.79	-4.02
Selling, General & Admin	5.34	5.99	5.75	5.43	5.57
Research & Development	12.54	-	-	-	-
Operating Expenses	17.88	5.99	5.75	5.43	5.57
Operating Income	-17.88	-21.16	-18.14	-14.22	-9.59
Interest Expense	-	-	-0	-0	-0.01
Interest & Investment Income	0.54	0.64	-	-	-
Currency Exchange Gain (Loss)	-0.16	-0.07	-0.02	-0.01	-
Other Non Operating Income (Expenses)	-	-	0.01	0.05	-0.05
EBT Excluding Unusual Items	-17.5	-20.58	-18.15	-14.19	-9.65
Impairment of Goodwill	-	-	-19.09	-	-
Legal Settlements	-	2.6	-1.6	-	-
Pretax Income	-17.5	-17.98	-38.84	-14.19	-9.65
Net Income	-17.5	-17.98	-38.84	-14.19	-9.65
Net Income to Common	-17.5	-17.98	-38.84	-14.19	-9.65
Shares Outstanding (Basic)	10	10	8	7	5
Shares Outstanding (Diluted)	10	10	8	7	5
Shares Change (YoY)	5.42%	18.52%	10.58%	60.04%	73.32%
EPS (Basic)	-1.72	-1.86	-4.77	-1.93	-2.10
EPS (Diluted)	-1.72	-1.86	-4.77	-1.93	-2.10
Free Cash Flow	-	-14.78	-21.51	-12.77	-10.07
Free Cash Flow Per Share	-	-1.53	-2.64	-1.73	-2.19
Gross Margin	-	-	-	-	-199.60%
Operating Margin	-	-	-	-	-475.97%
Profit Margin	-	-	-	-	-479.05%
Free Cash Flow Margin	-	-	-	-	-500.00%
EBITDA	-17.75	-20.97	-17.95	-14.03	-9.43
D&A For EBITDA	0.13	0.19	0.19	0.19	0.16
EBIT	-17.88	-21.16	-18.14	-14.22	-9.59

Updated Nov 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q